

1 **A cautionary note on recall vaccination in ex-COVID-19 subjects**

2

3 Riccardo Levi, MSc^{*1,2}, Elena Azzolini, MD PhD^{*1, 2}, Chiara Pozzi, PhD^{*2}, Leonardo Ubaldi, MSc^{1*},
4 Michele Lagioia², MD, Alberto Mantovani, MD^{1, 2, 3} and Maria Rescigno, PhD^{1, 2, #}

5

6 ¹Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090
7 Pieve Emanuele, Milan, Italy.

8 ²IRCSS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.

9 ³The William Harvey Research Institute, Queen Mary University of London, London, UK

10

11 *These authors contributed equally

12

13

14

15 #Corresponding author:

16 E-mail: maria.rescigno@hunimed.eu

17 Humanitas University

18 Via Rita Levi Montalcini, 4

19 20090 Pieve Emanuele (Mi) Italy

20

21

22 **Abstract**

23 Currently approved COVID-19 vaccines based on mRNA or adenovirus require a first jab followed
24 by recall immunization. There is no indication as to whether individuals who have recovered from
25 COVID-19 should be vaccinated, and if so, if they should receive one or two vaccine doses.
26 Here, we tested the antibody response developed after the first dose of the mRNA based vaccine
27 encoding the SARS-CoV-2 full-length spike protein (BNT162b2) in 124 healthcare professionals of
28 which 57 had a previous history of COVID-19 (ExCOVID). Post-vaccine antibodies in ExCOVID
29 individuals increase exponentially within 7-15 days after the first dose compared to naïve subjects
30 ($p < 0.0001$). We developed a multivariate Linear Regression (LR) model with l2 regularization to
31 predict the IgG response for SARS-COV-2 vaccine. We found that the antibody response of
32 ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed
33 during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most
34 significantly positively correlated in the LR. Thus, one vaccine dose is sufficient to induce a good
35 antibody response in ExCOVID subjects. This poses caution for ExCOVID subjects to receive a
36 second jab both because they may have a overreaction of the inflammatory response and also in
37 light of the current vaccine shortage.

38

39 **Introduction**

40 Currently approved COVID-19 vaccines based on mRNA¹⁻³ or adenovirus⁴ require a first jab
41 followed by recall immunization. The impact of previous exposure to SARS-CoV-2 on immune
42 response elicited the vaccines has not been assessed.

43

44 **Methods**

45 We tested the antibody response developed after the first dose of the mRNA based vaccine
46 encoding the SARS-CoV-2 full-length spike protein (BNT162b2)¹ in 124 healthcare professionals of
47 which 57 had a previous history of COVID-19 (ExCOVID) (Table 1), as part of an observational
48 study (clinicaltrial.gov NCT04387929) conducted at Istituto Clinico Humanitas in which healthcare

49 professionals were followed for serology and for any occurring COVID-19 related symptoms every
50 three months⁵. We recorded the antibody response to Spike 1/2 with a quantitative test (Liaison
51 SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy) which allowed us to evaluate even large amounts
52 of plasma IgG. To predict the IgG response for SARS-COV-2 vaccine, a multivariate Linear
53 Regression (LR) model with l2 regularization (also known as Ridge Regression) was developed.
54 Numerical variables were standardized (z-score algorithm) and the target variable was log
55 transformed due to right asymmetry of the distribution. The subjects without the serological
56 analysis before vaccination were excluded from this analysis (n=11). The final number of subjects
57 analyzed in LR was 113.

58

59 **Results**

60 As shown in Fig.1A-B ExCOVID individuals had a much higher antibody response after the first
61 dose of vaccine than naïve subjects ($p<0.0001$), regardless of when they developed the COVID-
62 19. They displayed an exponential increase of anti-Spike 1/2 antibody response within 7-15 days
63 after the first dose of vaccine. The pre-vaccine antibody amount of the ExCOVID population was
64 on average 44.+/-37.7 while that after the vaccine was 1055.7+/-1004.2 ($p<0.0001$) (Table 1), with
65 higher levels in symptomatic ExCOVID (Fig. 1C, $p=0.028$).

66 We investigated the relationship between the amount of IgG after vaccination with COVID-19, sex,
67 age and symptoms related to disease. The final LR shows a good prediction of the target variable
68 ($R^2=0.88$, F-statistic = 39.18, p -value <0.001) and the most significant features were history of
69 COVID-19 (1.48, 95% CI 1.07-1.93), the value of IgG before vaccination (0.87, 95% CI 0.59-1.13),
70 the difference between the date of vaccination and the date of serology post-vax (0.87, 95% CI
71 0.65-1.03), and age (-0.13, 95% CI -0.24 - -0.001) as well as COVID-19 related symptoms:
72 gastrointestinal disorders (0.59, 95% CI 0.16-0.97), anosmia/dysgeusia (0.50, 95% CI 0.14-0.87),
73 tachycardia (0.26, 95% CI 0.02-0.60) and sore throat (-0.35, 95% CI -0.53 - -0.11) (Fig. 1D, Suppl.
74 Table1).

75

76 **Discussion**

77 The antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the
78 symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal
79 disorders being the most significantly positively correlated in the LR, while sore throat was
80 negatively correlated because 45% non-COVID individuals reported it. Young subjects had a
81 higher antibody response. We previously observed that anosmia/dysgeusia was associated with
82 an increase of antibodies over time, independently of vaccination (Levi et al. submitted). Thus, one
83 vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects and poses
84 caution for a second dose: over stimulation with high amount of antigens could switch-off the
85 immune response due to antigen exhaustion, which occurs in response to several viruses
86 (reviewed in⁶). Alternatively, overactivation of the immune response may drive the development of
87 low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement
88 (ADE) reaction when re-exposed to the virus (reviewed in⁷). These results question whether a
89 second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring
90 antibody response longevity. At a time of vaccine scarcity, these findings may have public health
91 implications.

92

93

94

95 **References**

- 96 1. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-
97 Based Covid-19 Vaccine Candidates. *N Engl J Med.* 2020;383(25):2439-2450.
- 98 2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA
99 Covid-19 Vaccine. *N Engl J Med.* 2020;383(27):2603-2615.
- 100 3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-
101 CoV-2 Vaccine. *N Engl J Med.* 2020.

- 102 4. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19
103 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
104 controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111.
- 105 5. Sandri MT, Azzolini E, Torri V, et al. SARS-CoV-2 serology in 4000 health care and
106 administrative staff across seven sites in Lombardy, Italy. *medRxiv*.
107 2020:2020.2005.2024.20111245.
- 108 6. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion.
109 *Immunology*. 2010;129(4):474-481.
- 110 7. Flanagan KL, Best E, Crawford NW, et al. Progress and Pitfalls in the Quest for Effective
111 SARS-CoV-2 (COVID-19) Vaccines. *Front Immunol*. 2020;11:579250.
112
113

A

| | | Serology pre VAX | | | | | | | |
|-----------|---------------|------------------|-------|-----|------|-------|-------|------|-------|
| | | counts | % | min | max | mean | std | TEST | p |
| COVID-19 | NO (Healthy) | 67 | 59.29 | 3 | 7.66 | 3.35 | 1.02 | MW | 5E-12 |
| | YES (ExCOVID) | 46 | 40.71 | 3 | 140 | 44.58 | 37.72 | | |
| GENDER | F | 63 | 55.75 | 3 | 132 | 18.86 | 28.46 | MW | 0.295 |
| | M | 50 | 44.25 | 3 | 140 | 21.74 | 34.99 | | |
| Age_class | 21-30 | 24 | 21.24 | 3 | 140 | 29.25 | 38.82 | MW | 0.027 |
| | 31-40 | 37 | 32.74 | 3 | 132 | 16.56 | 28.14 | MW | 0.086 |
| | 41-50 | 31 | 27.43 | 3 | 81.7 | 14.76 | 22.91 | MW | 0.074 |
| | 51-60 | 13 | 11.5 | 3 | 123 | 25.73 | 42.37 | KS | 0.146 |
| | 60+ | 8 | 7.08 | 3 | 78.1 | 21.12 | 29.81 | KS | 0.986 |

B

| | | Serology post VAX | | | | | | | | |
|------------------------------|----------------------------|-------------------|-------|-------|------|--------|--------|--------|-------|-------|
| | | counts | % | min | max | mean | std | TEST | p | |
| COVID-19 | NO (Healthy) | 67 | 54.03 | 3 | 104 | 13.29 | 19.73 | MW | 3E-19 | |
| | YES (ExCOVID) | 57 | 45.97 | 3 | 4000 | 1055.7 | 1004.2 | | | |
| GENDER | F | 71 | 57.26 | 3 | 3800 | 466.97 | 875.9 | MW | 0.455 | |
| | M | 53 | 42.74 | 3 | 4000 | 526.62 | 833.75 | | | |
| Age_class | 21-30 | 30 | 24.19 | 3 | 4000 | 601.13 | 901.65 | MW | 0.015 | |
| | 31-40 | 39 | 31.45 | 3 | 3800 | 553.52 | 1046.9 | MW | 0.115 | |
| | 41-50 | 33 | 26.61 | 3 | 2320 | 351.12 | 644.59 | MW | 0.234 | |
| | 51-60 | 14 | 11.29 | 3 | 2240 | 437.95 | 740.98 | KS | 0.986 | |
| | 60+ | 8 | 6.45 | 3 | 1690 | 465.76 | 664.78 | KS | 0.696 | |
| CLASS SYMPTOMS (for ExCOVID) | a/paucisymptomatic | 15 | 26.32 | 3 | 1800 | 507.73 | 598.39 | KS | 0.029 | |
| | symptomatic | 42 | 73.68 | 10.7 | 4000 | 1251.4 | 1051.6 | | | |
| ExCOVID | Fever | 0 | 30 | 52.63 | 3 | 3800 | 865.65 | 942.76 | MW | 0.034 |
| | | 1 | 27 | 47.37 | 10.7 | 4000 | 1266.9 | 1045.2 | | |
| | Low-grade Fever | 0 | 44 | 77.19 | 3 | 4000 | 954.8 | 1060.1 | KS | 0.016 |
| | | 1 | 13 | 22.81 | 27 | 2630 | 1397.2 | 717.47 | | |
| | Headache | 0 | 31 | 54.39 | 3 | 2520 | 825.63 | 734.51 | MW | 0.038 |
| | | 1 | 26 | 45.61 | 27 | 4000 | 1330 | 1211.4 | | |
| | Cough | 0 | 40 | 70.18 | 3 | 3800 | 921.12 | 959.53 | KS | 0.176 |
| | | 1 | 17 | 29.82 | 8.18 | 4000 | 1372.4 | 1064.5 | | |
| | Sore throat | 0 | 31 | 54.39 | 3 | 3330 | 1040.9 | 857.41 | MW | 0.365 |
| | | 1 | 26 | 45.61 | 8.18 | 4000 | 1073.4 | 1173 | | |
| | Muscle pain | 0 | 27 | 47.37 | 3 | 4000 | 864.43 | 1100.9 | MW | 0.013 |
| | | 1 | 30 | 52.63 | 10.7 | 3330 | 1227.9 | 892.15 | | |
| | Asthenia | 0 | 25 | 43.86 | 3 | 2520 | 717.64 | 784.71 | MW | 0.008 |
| | | 1 | 32 | 56.14 | 10.7 | 4000 | 1319.8 | 1086.6 | | |
| | Anosmia/dysgeusia | 0 | 29 | 50.88 | 3 | 4000 | 824.28 | 1044.4 | MW | 0.009 |
| | | 1 | 28 | 49.12 | 27 | 3800 | 1295.4 | 918.26 | | |
| | Gastrointestinal disorders | 0 | 33 | 57.89 | 8.18 | 2520 | 902.12 | 753.36 | MW | 0.212 |
| | | 1 | 24 | 42.11 | 3 | 4000 | 1266.9 | 1259 | | |
| | Conjunctivitis | 0 | 49 | 85.96 | 3 | 4000 | 1018.2 | 984.56 | KS | 0.896 |
| | | 1 | 8 | 14.04 | 27 | 3330 | 1285.8 | 1161.6 | | |

| | | | | | | | | | | |
|--|-----------------------------------|----------|----|-------|------|------|--------|--------|----|-------|
| | Dyspnea | 0 | 41 | 71.93 | 3 | 4000 | 952.52 | 1017.5 | KS | 0.179 |
| | | 1 | 16 | 28.07 | 27 | 3330 | 1320.1 | 948.76 | | |
| | Chest pain | 0 | 42 | 73.68 | 3 | 4000 | 989.3 | 988.56 | KS | 0.819 |
| | | 1 | 15 | 26.32 | 27 | 3330 | 1241.6 | 1058.9 | | |
| | Tachycardia | 0 | 47 | 82.46 | 3 | 3800 | 982.11 | 870.62 | KS | 0.395 |
| | | 1 | 10 | 17.54 | 27 | 4000 | 1401.6 | 1496.3 | | |
| | Pneumonia | 0 | 50 | 87.72 | 3 | 4000 | 1013.9 | 1036.5 | KS | 0.218 |
| | | 1 | 7 | 12.28 | 27 | 2240 | 1354.3 | 720.25 | | |
| | Fever | 0 | 63 | 94.03 | 3 | 104 | 13.45 | 20.13 | KS | 0.995 |
| | | 1 | 4 | 5.97 | 3 | 30.7 | 10.74 | 13.4 | | |
| | Low-grade Fever | 0 | 62 | 92.54 | 3 | 104 | 14.04 | 20.33 | KS | 0.559 |
| | | 1 | 5 | 7.46 | 3 | 6.26 | 3.9 | 1.42 | | |
| | Headache | 0 | 42 | 62.69 | 3 | 104 | 12.68 | 20.73 | MW | 0.438 |
| | | 1 | 25 | 37.31 | 3 | 60.5 | 14.3 | 18.28 | | |
| | Cough | 0 | 51 | 76.12 | 3 | 104 | 12.52 | 20.12 | KS | 0.126 |
| | | 1 | 16 | 23.88 | 3 | 63.8 | 15.72 | 18.85 | | |
| | Sore throat | 0 | 37 | 55.22 | 3 | 60.5 | 11.02 | 15.69 | MW | 0.256 |
| | | 1 | 30 | 44.78 | 3 | 104 | 16.08 | 23.78 | | |
| | Muscle pain | 0 | 58 | 86.57 | 3 | 104 | 12.54 | 19.49 | KS | 0.724 |
| | | 1 | 9 | 13.43 | 3 | 55.9 | 18.11 | 21.79 | | |
| | Asthenia | 0 | 56 | 83.58 | 3 | 104 | 12.23 | 19.47 | KS | 0.419 |
| | | 1 | 11 | 16.42 | 3 | 49.7 | 18.68 | 21.11 | | |
| | Anosmia/dysgeusia | 0 | 66 | 98.51 | 3 | 104 | 13.4 | 19.86 | KS | 0.687 |
| | | 1 | 1 | 1.49 | 6.13 | 6.13 | 6.13 | | | |
| | Gastrointestinal disorders | 0 | 58 | 86.57 | 3 | 104 | 13.3 | 20.1 | KS | 0.656 |
| | | 1 | 9 | 13.43 | 3 | 55.9 | 13.2 | 18.24 | | |
| | Conjunctivitis | 0 | 60 | 89.55 | 3 | 63.8 | 11.5 | 16.12 | KS | 0.419 |
| | | 1 | 7 | 10.45 | 3 | 104 | 28.62 | 37.68 | | |
| | Dyspnea | 0 | 64 | 95.52 | 3 | 104 | 13.75 | 20.07 | KS | 0.399 |
| | | 1 | 3 | 4.48 | 3 | 4.5 | 3.5 | 0.87 | | |
| | Chest pain | 0 | 63 | 94.03 | 3 | 104 | 13.92 | 20.19 | KS | 0.205 |
| | | 1 | 4 | 5.97 | 3 | 4.4 | 3.35 | 0.7 | | |
| | Tachycardia | 0 | 62 | 92.54 | 3 | 104 | 14.07 | 20.32 | KS | 0.195 |
| | | 1 | 5 | 7.46 | 3 | 4.57 | 3.61 | 0.84 | | |
| | Pneumonia | 0 | 67 | 100 | 3 | 104 | 13.29 | 19.73 | na | na |
| | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | | |

C

| | | counts | % | min | max | mean | std | TEST | <i>p</i> |
|---|----------------|--------|-------|------|------|-------|------|------|----------|
| Days between VAX and serology post VAX | Healthy | 67 | 54.03 | 4.8 | 16.9 | 8.9 | 2.91 | MW | 3E-08 |
| | ExCOVID | 57 | 45.97 | 4.89 | 20.4 | 13.81 | 4.91 | | |

114

115

Table 1. A.B. Demographic distribution of anti-Spike 1/2 IgG plasma levels. C. Days between


116

vaccination and serology post vaccination. *P* values determined using two-tailed unpaired Mann–

117

Whitney test (MW) or two-tailed unpaired Kolmogorov-Smirnov test (KS). NA: not applicable.

118



119

120

121 **Figure 1: ExCOVID subjects increase exponentially anti-Spike 1/2 Ig levels after the first**
 122 **dose of vaccine.** A, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals
 123 (n=57) measured after the first dose of vaccine. B, anti-Spike 1/2 IgG plasma levels in healthy
 124 (n=67) and ExCOVID individuals (n=46) measured before and after the first dose of vaccine. C,
 125 anti-Spike 1/2 IgG plasma levels in asymptomatic / paucisymptomatic (n=15) and in symptomatic
 126 (n=42) ExCOVID individuals measured after the first dose of vaccine. D, Multivariate linear
 127 regression coefficients for the most significant variables ($p < 0.05$). Dot points represent the mean
 128 values and the lines the 95% CI.

129 The box plots (A, C) show the interquartile range, the horizontal lines show the median values and
130 the whiskers indicate the minimum-to-maximum range. *P* values were determined using two-tailed
131 unpaired Mann–Whitney test (A) or two-tailed Wilcoxon matched-pairs signed rank test (B) or two-
132 tailed unpaired Kolmogorov-Smirnov test (C).
133